Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 19,353 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Efficacy and Safety Clear all
Completed Phase 1Phase 2 Interventional Results available

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

NCT02311582
View directory record Official record
Conditions
Malignant Glioma
Interventions
MK-3475, MRI-guided laser ablation
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trim II for Noninvasive Lipolysis and Circumference Reduction of Abdomen.

NCT05398159
View directory record Official record
Conditions
Circumference Reduction of Abdomen
Interventions
Trim II
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Huntersville, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 22, 2026, 1:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496
View directory record Official record
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Fulvestrant, Capivasertib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162
View directory record Official record
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Recruiting Phase 3 Interventional

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903
View directory record Official record
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Nucresiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
45
States / cities
La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 2 Interventional Results available

Bexarotene Amyloid Treatment for Alzheimer's Disease

NCT01782742
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT00051142
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

NCT00827242
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo, tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children

NCT01431170
View directory record Official record
Conditions
Congenital Nasolacrimal Duct Obstruction
Interventions
Besivance Treatment Group, Polytrim Treatment Group
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
1 Month to 12 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 22, 2026, 1:05 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

NCT02353754
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine injection, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Port Saint Lucie, Florida • Minneapolis, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

NCT01907854
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

NCT06102005
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

NCT07021066
View directory record Official record
Conditions
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Other Solid Tumors
Interventions
BL-M05D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

NCT06325566
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Rexlemestrocel-L + HA mixture, Saline
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

NCT04503551
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 3 Interventional

DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up

NCT00444353
View directory record Official record
Conditions
Nasolabial Fold Wrinkles
Interventions
DL6049 (injectable poly-L-lactic acid)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

NCT03201562
View directory record Official record
Conditions
Presbyopia
Interventions
Aceclidine+tropicamide combination, Aceclidine, Vehicle
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
48 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746
View directory record Official record
Conditions
Acute Leukaemia
Interventions
Daunorubicin, Cytarabine, Eltrombopag, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

NCT00813488
View directory record Official record
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablet, Immediate release oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 22, 2026, 1:05 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Stavudine, Didanosine
Drug
Lead sponsor
Research Institute for Genetic and Human Therapy
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 1:05 PM EDT
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

NCT00458861
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924, Placebo Comparator
Biological · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 22, 2026, 1:05 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 22, 2026, 1:05 PM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 22, 2026, 1:05 PM EDT